Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
VK0214, oral TR agonist for X-linked adrenoleukodystrophy (X-ALD) Recent Highlights: In June 2026, Viking announced that its working toward maintenance-dosing data for subcutaneous VK2735 and preparing to start Phase 3 trials of the oral tablet in Q4 2026, with the goal of becoming the first company to offer a dual GLP-1/GIP agonist in both oral and injectable form
The test ($298) analyzes your GIPR genetic variants to reveal whether your receptors respond optimally to extended-interval stimulation or require weekly dosing for best results
Spain 14.11
Through its modulation of the NNMT-SAM-NAD+ axis, it enhances energy expenditure and supports more efficient utilization of fat stores for energy, making it a strong candidate in studies exploring metabolic optimization and obesity control
At 5 mg/mL, notice that a 0.25 mg dose is only 5 units
US$ 25.17
US$ 25.56
US$ 22.22
US$ 21.37
